Onesource Specialty Pharma · NSE: ONESOURCE · BSE: 544292
Q3 FY26 results · Oct–Dec 2025
Onesource Specialty Pharma reported revenue from operations of ₹290.34 crore (down 26.0% from Q3 FY25) and net loss of ₹88.70 crore for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 290.34 | 392.56 | −26.0% | 375.76 | −22.7% |
| Other income | 4.62 | 5.39 | −14.2% | 3.04 | +52.3% |
| Total income | 294.96 | 397.96 | −25.9% | 378.80 | −22.1% |
| Profit before tax | (93.01) | (66.50) | Loss widened | 5.74 | Turned loss |
| Net profit for the period | (88.70) | (68.85) | Loss widened | 10.48 | Turned loss |
| EPS, basic (₹) | (7.74) | (6.31) | Loss widened | 0.92 | Turned loss |
| Net margin (%) | -30.6 | -17.5 | 2.8 |
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 290.22 | 336.75 | −13.8% | 375.19 | −22.6% |
| Other income | 4.62 | 5.01 | −7.8% | 3.04 | +52.3% |
| Total income | 294.84 | 341.76 | −13.7% | 378.22 | −22.0% |
| Profit before tax | (62.19) | (73.02) | Loss narrowed | 37.10 | Turned loss |
| Net profit for the period | (62.19) | (73.02) | Loss narrowed | 37.10 | Turned loss |
| EPS, basic (₹) | (5.43) | (6.69) | Loss narrowed | 3.24 | Turned loss |
| Net margin (%) | -21.4 | -21.7 | 9.9 |
Consolidated
- Filed with BSE
- 23 Jan 2026, 21:27 IST
- Board meeting
- 23 Jan 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 23 Jan 2026, 21:27 IST
- Board meeting
- 23 Jan 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE